NYSE - Delayed Quote USD

Novo Nordisk A/S (NVO)

126.85 +1.06 (+0.84%)
At close: April 26 at 4:00 PM EDT
127.30 +0.45 (+0.35%)
After hours: April 26 at 7:59 PM EDT
Currency in DKK All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
232,261,000.00
232,261,000.00
176,954,000.00
140,800,000.00
126,946,000.00
Cost of Revenue
35,765,000.00
35,765,000.00
28,448,000.00
23,658,000.00
20,932,000.00
Gross Profit
196,496,000.00
196,496,000.00
148,506,000.00
117,142,000.00
106,014,000.00
Operating Expense
93,922,000.00
93,922,000.00
73,697,000.00
58,498,000.00
51,888,000.00
Operating Income
102,574,000.00
102,574,000.00
74,809,000.00
58,644,000.00
54,126,000.00
Net Non Operating Interest Income Expense
330,000.00
330,000.00
-320,000.00
-180,000.00
-203,000.00
Other Income Expense
1,770,000.00
1,770,000.00
-5,427,000.00
616,000.00
-793,000.00
Pretax Income
104,674,000.00
104,674,000.00
69,062,000.00
59,080,000.00
53,130,000.00
Tax Provision
20,991,000.00
20,991,000.00
13,537,000.00
11,323,000.00
10,992,000.00
Net Income Common Stockholders
83,683,000.00
83,683,000.00
55,525,000.00
47,757,000.00
42,138,000.00
Diluted NI Available to Com Stockholders
83,683,000.00
83,683,000.00
55,525,000.00
47,757,000.00
42,138,000.00
Basic EPS
18.67
18.67
12.26
10.40
9.03
Diluted EPS
18.62
18.62
12.22
10.37
9.01
Basic Average Shares
4,482,800.00
4,482,800.00
4,530,600.00
4,593,200.00
4,667,800.00
Diluted Average Shares
4,494,800.00
4,494,800.00
4,544,600.00
4,606,200.00
4,680,000.00
Total Operating Income as Reported
102,574,000.00
102,574,000.00
74,809,000.00
58,644,000.00
54,126,000.00
Total Expenses
129,687,000.00
129,687,000.00
102,145,000.00
82,156,000.00
72,820,000.00
Net Income from Continuing & Discontinued Operation
83,683,000.00
83,683,000.00
55,525,000.00
47,757,000.00
42,138,000.00
Normalized Income
82,333,489.00
82,333,489.00
59,736,352.00
47,239,880.00
42,885,006.00
Interest Income
1,069,000.00
1,069,000.00
239,000.00
231,000.00
337,000.00
Interest Expense
542,000.00
542,000.00
378,000.00
289,000.00
390,000.00
Net Interest Income
330,000.00
330,000.00
-320,000.00
-180,000.00
-203,000.00
EBIT
105,216,000.00
105,216,000.00
69,440,000.00
59,369,000.00
53,520,000.00
EBITDA
114,629,000.00
114,629,000.00
76,802,000.00
65,394,000.00
59,273,000.00
Reconciled Cost of Revenue
35,765,000.00
35,765,000.00
28,448,000.00
23,658,000.00
20,932,000.00
Reconciled Depreciation
9,413,000.00
9,413,000.00
7,362,000.00
6,025,000.00
5,753,000.00
Net Income from Continuing Operation Net Minority Interest
83,683,000.00
83,683,000.00
55,525,000.00
47,757,000.00
42,138,000.00
Total Unusual Items Excluding Goodwill
1,689,000.00
1,689,000.00
-5,238,000.00
640,000.00
-942,000.00
Total Unusual Items
1,689,000.00
1,689,000.00
-5,238,000.00
640,000.00
-942,000.00
Normalized EBITDA
112,940,000.00
112,940,000.00
82,040,000.00
64,754,000.00
60,215,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
339,489.00
339,489.00
-1,026,648.00
122,880.00
-194,994.00
12/31/2020 - 4/30/1981

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VKTX Viking Therapeutics, Inc.
74.31
+7.91%
 
VRTX Vertex Pharmaceuticals Incorporated
397.48
-0.06%
 
MRNA Moderna, Inc.
107.97
+1.69%
 
CRSP CRISPR Therapeutics AG
53.91
+0.34%
 
RXRX Recursion Pharmaceuticals, Inc.
8.12
+3.57%
 
REGN Regeneron Pharmaceuticals, Inc.
883.20
-0.84%
 
IBRX ImmunityBio, Inc.
7.35
+43.84%
 
ALT Altimmune, Inc.
7.26
+0.83%
 
NVAX Novavax, Inc.
4.0900
+3.54%
 
MDGL Madrigal Pharmaceuticals, Inc.
193.33
-0.54%